Processa Pharmaceuticals, Inc.
PCSA
$2.55
-$0.01-0.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.18M | 5.61M | 4.92M | 4.77M | 4.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.99M | 13.02M | 12.96M | 12.09M | 12.05M |
| Operating Income | -13.99M | -13.02M | -12.96M | -12.09M | -12.05M |
| Income Before Tax | -13.56M | -12.93M | -12.88M | -11.96M | -11.85M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.56 | -12.93 | -12.88 | -11.96 | -11.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.56M | -12.93M | -12.88M | -11.96M | -11.85M |
| EBIT | -13.99M | -13.02M | -12.96M | -12.09M | -12.05M |
| EBITDA | -13.99M | -13.02M | -12.96M | -12.09M | -12.05M |
| EPS Basic | -17.05 | -34.98 | -59.00 | -77.91 | -98.10 |
| Normalized Basic EPS | -10.66 | -21.86 | -36.87 | -48.69 | -61.31 |
| EPS Diluted | -17.05 | -34.98 | -59.00 | -77.91 | -98.10 |
| Normalized Diluted EPS | -10.66 | -21.86 | -36.87 | -48.69 | -61.31 |
| Average Basic Shares Outstanding | 5.16M | 3.05M | 1.28M | 772.00K | 489.60K |
| Average Diluted Shares Outstanding | 5.16M | 3.05M | 1.28M | 772.00K | 489.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |